[서울=뉴스핌] Reporter Seo Young-wook = Daewoong Pharmaceutical announced on the 20th that it has completely eliminated the risk of the U.S.’Nabota’ business through an agreement between Medytox and U.S. partners Evolus and AbbVie.
However, Daewoong Pharmaceutical said, “I am not a party to this agreement and I have never agreed in advance.”
 |
| View of Daewoong Pharmaceutical Head Office [제공=대웅제약] |
Earlier, on the 19th, Medytox and Medytox’s partner AbbVie, USA, and Daewoong Pharmaceutical’s U.S. partner Evolus, signed a three-party agreement.
According to the agreement, Daewoong Pharmaceutical’s botulinum toxin formulation’Nabota’ (U.S. product name bulletin) can be sold in the US in the future. Instead, whenever Nabota is sold in the United States, Ebolus has to pay a certain amount to Medytox and Abbey.
Daewoong Pharmaceutical said, “The reason Ebolus agreed to the agreement was that it was made entirely based on management judgment in order to avoid disruption of the company’s business activities while the US International Trade Commission (ITC) issued a 21-month import ban on bulletins.” .
However, he drew a line that he did not intervene in the agreement, saying, “I am not a party to this agreement and I have never agreed in advance.”
Daewoong Pharmaceutical said, “This agreement completely eliminates business risks in the US and lays the foundation for resuming Nabota sales. Based on Nabota’s advanced quality and technology, we are advancing into the global market with Evolus. I will spur it.”
Daewoong Pharmaceutical is planning to actively respond to civil and criminal lawsuits filed in Korea.